McLaren Thumb, Caro regions loosening visitor restrictions
Declining COVID numbers allow patients to have visitors
FacebookTwitterEmail
McLaren Thumb Region in Bad Axe. (Tribune File Photo)
McLaren Thumb Region and Caro Region hospitals have updated their visitor restrictions thanks to the recent reduction of COVID-19 cases in the Upper Thumb region and across the state.
The new restrictions for visitors coming into McLaren include:
• Each inpatient and emergency room patient may have one healthy adult visitor
• Pediatric patients may have up to two healthy adult visitors, either parents or legal guardians.
• Obstetrical patients may have up to two support persons.
• Patients being evaluated for or on hospice care or nearing the end of life may have two visitors.
Forsyth County has been moved from the most to least severe county alert category for COVID-19, the N.C. Department of Health and Human Services announced Monday.
The planned Group Three vaccinations scheduled to begin Wednesday likely have become more complicated â at least in the short term â because of the winter cold snapâs effect on first dose supplies.
The N.C. Department of Health and Human Services announced Friday that the rounds of vaccine expected to have arrived Feb. 16-17 from federal government supplies wonât be available for distribution until between Monday and Wednesday.
âAllocations for the next week are also expected to arrive during the same time period,â DHHS said.
âTypically, providers receive COVID-19 vaccine shipments of first doses on Tuesday and Wednesday and shipments of second doses on Thursday and Friday.â
Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIES® Systems. These 6- and 12-cassette systems are automated molecular diagnostic platforms used in moderate- and high-complexity labs with a number of FDA cleared tests already available for use on them. The systems produce results in less than two hours with minimal hands-on time required.